An interventional study of Ropivacaine in Postoperative Pain, sponsored by Third Military Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-10.
Sponsored by Third Military Medical University · Not applicable, Interventional, and Treatment
Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.
Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 71st largest by enrollment, is one of 12 that started in 2018, is one of 61 with no phase, and was the 105th registered.
5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.
This study's enrollment of 80 is close to the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Each count lists the studies.
Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 241 (35%) set no upper age limit and 328 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →184 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 12 started in 2018.
Median enrollment 70 across the 184 interventional studies. Of the 125 that completed or were terminated, 32 (26%) have results posted.
6 of 184 have an industry lead sponsor. The 10 most frequent:
Third Military Medical University is the lead sponsor of 83 studies on the registry; 17 are open to participants now.
Third Military Medical University has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
6 of the studies testing ropivacaine in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03230565Stanford UniversityContinuous Infusions vs Scheduled Bolus Infusions | 2026-12 |
| NCT06189781University of California, Los AngelesPain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy | 2026-12-30 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
| NCT07704970Huazhong University of Science and TechnologyQLESP Block for Pain Control in Robotic Partial Nephrectomy | 2027-02-28 |
| NCT07853482Maternity Hospital - State Budgetary Institution of the Rostov Region, TaganrogTAP vs. ESP Blocks for Post-Cesarean Analgesia | 2027-05-10 |
Among the 184 studies testing ropivacaine in Pain, Postoperative, from their registry updates:
Quadratus lumborum block can be used for the hip surgery and abdominal surgery postoperative analgesia. But the lower thoracic to the hip dermatome can't be blocked at the same time. The anesthetists used the same method, but had produced the different dermatome were blocked. The investigators hypothesized that this was due to local anesthetics was injected to different locations of the anterior thoracolumbar fascia. If the investigators inject local anesthetics to the anterior layer of thoracolumbar extrafascial, this produced the dermatomal coverage from lower abdominal to hip. A different situation was when the investigators injected local anesthetics to anterior thoracolumbar subfascia, the lower thoracic dermatome were blocked.
Quadratus lumborum block can be used for the hip surgery and abdominal surgery postoperative analgesia. But the lower thoracic to the hip dermatomes can't be blocked at the same time. The anesthetists used the same method, but had produced the different dermatomes were blocked. The investigators hypothesized that this was due to local anesthetics was injected to different locations of the anterior thoracolumbar fascia. If the investigators inject local anesthetics to the anterior thoracolumbar extrafascial (between the anterior layer of thoracolumbar fascia and psoas major muscle), this produced the dermatomal coverage from lower abdominal to hip. In this case, the investigators speculated the local anesthetic spread to the lumbar paravertebral space via the fascia and the fascicle of psoas major. A different situation was when the investigators injected local anesthetics to anterior thoracolumbar subfascial (between the anterior layer of thoracolumbar fascia and quadratus lumborum), the lower thoracic dermatomes were blocked. The investigators speculate that the local anesthetic injected subfascial could spread cephalad to lower thoracic paravertebral space posterior to the endothoracic fascia via lateral arcuate ligament.
The investigators confirm the hypothesis in the pilot trial. therefore, the investigators need to trial with large sample. The investigators plan to improve the clinical guidance of quadratus lumborum block technology, so that more patients benefit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 ml of 0.33% ropivacaine was injected to subfascial.
Drug: Ropivacaine
30 ml of 0.33% ropivacaine was injected to extrafascial.
Drug: Ropivacaine
Subfascial injection OR extrafascial injection
Also known as: Naropin
Changes of pain intensity of the 3 holes at 48 hours post-operation
The three holes include the Subxiphoid hole, Subcostal hole and supraumbilical hole in the laparoscopic cholecystectomy. Patients reported pain intensity of each hole in the post-operation of 1 hour, 6 hours, 12 hours, 24 hours, 36 hours and 48 hours. Each item is scored 0-10 (0 = no pain; 10= pain as bad as can be).
Time frame: 48 hours after operation
Adverse effects
Included the Postoperative nausea and vomiting (PONV),pruritus, gastroduodenal ulcer and local anaesthetics toxicity.
Time frame: 48 hours after operation
Limbs weakness
Record according to the modified Lovett rating scale (LRS). It was defined as follows: 0 = complete paralysis; 1 = almost complete paralysis; 2 = pronounced mobility impairment; 3 = slightly impaired mobility; 4 = pronounced reduction of muscular force; 5 = slightly reduced muscular force; 6 = normal muscular force.
Time frame: at 30 min after block
Postoperative analgesic consumption
The observer recorded the consumption of parecoxib sodium and fentanyl and the point of administered time within 48 hours after operation
Time frame: 48 hours after operation
dependent ambulation
The proportion of dependent ambulation assistance at 1 and 6 hours after surgery in the two groups.
Time frame: at 1 and 6 hours after surgery
Sensory block level
The sensory level was assessed with cold sensation (ice cube) in each dermatomal distribution from T4 to L5 every 5 minutes for 4 times.
Time frame: 30 min after blocked
patients satisfaction
Patient satisfaction was assessed using a scale of 0-10, 10 being the most satisfied, at postoperative 48 hours.
Time frame: 48 hours after operation
Plan to share: Yes — De-identified individual participants data for all primary and secondary outcome measure will be made available.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Data will be available within 6 months of study completion.
Access criteria: Data access requests will be reviewed by an external Independent Review Panel. Requestors will be required to sign a data access agreement.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
Third Military Medical University